The tweet was deleted by the author.
But we saved everything 🙂.
Becton Dickinson is promoting innovative strategies to tackle safety obstacles related to hazardous drugs and support continuous improvement across organizations.
The company states that protecting teams begins with smarter solutions. Details are available through links provided in its announcement.
BDX is trading well below key averages, with the current price of $154.51 sitting far beneath the MA-20 at $163.29, MA-50 at $181.47, and MA-200 at $185.78. This structure signals persistent short-, medium-, and long-term selling pressure. The Ichimoku Kijun on D1 stands at $170.56 and acts as immediate resistance. For near-term support, the closest active level is the 52-week low at $153.76. Key support sits at MA-5 ($156.39). Immediate resistance is the Ichimoku Kijun ($170.56), with further resistance at MA-20 ($163.29) and MA-50 ($181.47).
Momentum on D1 remains firmly negative, with MACD and ADX supporting a clear downtrend. Weak RSI (32.96) and CCI (–64.16) point to persistent bearish momentum but are approaching oversold conditions, while Stoch RSI is elevated and signals overbought, which contradicts the broader picture. BBP is deeply negative at 0.02, revealing seller dominance. The AO reading is neutral and does not confirm the main trend direction. BDX is trading at $154.51, up slightly from last week's close of $154.13, a move of just 0.25%. Price is at the very bottom of the weekly range. Weekly volatility stands at 3.96%, and price action shows a steady decline from the high. In today's session, BDX fell by 1.82%, intensifying the bearish tone.
Looking ahead, the expected price range for the coming week is $153.50 to $156.80, bracketing the current price and keeping moves close to recent lows given the proximity to the 52-week low ($153.76) and far below the 52-week high ($229.80). With all major W1 indicators (MACD, ADX, RSI, SMA-50) firmly set to "Sell", the probability of an upward move is very low (less than 20%), making a decline markedly more likely. Baseline scenario: price remains range-bound between $153.50 and $156.80 as sellers continue to dominate. Bullish scenario: confirmation of a rebound would require breaking above $156.80, potentially targeting $163.29 if momentum shifts. Bearish scenario: a break below $153.50 would open the door to fresh 52-week lows, indicating further downside risk.
Previously it was reported that Becton Dickinson called for organizations to adopt innovative strategies to enhance hazardous drug safety and foster ongoing workplace improvements. As new industry dynamics emerge, investors should watch for shifts in regulatory momentum that could influence Becton Dickinson's operational positioning in the near term.